Literature DB >> 3875041

Effects of bepridil on transmembrane action potentials recorded from isolated canine cardiac tissues. Studies on normal and infarct-zone Purkinje fibres and ventricular muscle cells.

K H Dangman.   

Abstract

The electrophysiological effects of bepridil (1.9 mumol/l), a drug with antianginal and antiarrhythmic actions, were studied on transmembrane action potentials recorded from isolated cardiac tissues using standard microelectrode techniques. Recordings were made (a) from normal canine cardiac Purkinje fibres in major false tendons, (b) from partially depolarized subendocardial Purkinje fibres in 24 h infarct zones, and (c) from ventricular muscle preparations. It was found that at cycle lengths between 1000 and 300 ms, bepridil exerted use-dependent effects on the maximum rate of depolarization of phase zero (dV/dtmax) and action potential amplitude (APA) in both normal and infarct zone Purkinje fibres (IZPF), but that the effects in the IZPF were relatively greater. Bepridil did not affect maximum diastolic potential (MDP) in normal Purkinje fibres, but decreased it in IZPF. Bepridil lengthened total action potential duration under all conditions, but exerted variable effects on the duration of the plateau (APD-60 mV). In normal ventricular muscle cells (basic cycle length = 1000 ms), bepridil only decreased dV/dtmax. In regard to effects on automatic activity in canine Purkinje fibres, bepridil resembled slow inward current blocking drugs: it did not decrease the rate of normal automaticity or the slope of phase 4 depolarization in normal fibres (with MDPs greater than -80 mV), but it did slow or abolish abnormal automaticity in IZPF (with MDPs less than -60 mV). Bepridil also abolished triggering in 24 h IZPF.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875041     DOI: 10.1007/bf00501888

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Delayed development of ventricular ectopic rhythms following experimental coronary occlusion.

Authors:  A S HARRIS
Journal:  Circulation       Date:  1950-06       Impact factor: 29.690

2.  Some membrane interactions with bepridil, a new antianginal agent.

Authors:  C Labrid; A Grosset; G Dureng; J Mironneau; P Duchene-Marullaz
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

3.  Comparative antidysrhythmic profiles of bepridil, amiodarone and disopyramide in the guinea-pig and dog.

Authors:  C Labrid; M Leinot; M Beaughard; M Basiez; P Duchene-Marullaz
Journal:  Arch Int Pharmacodyn Ther       Date:  1981-01

4.  In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide.

Authors:  K H Dangman; B F Hoffman
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

5.  Supraventricular antidysrhythmic and electrophysiological effects of bepridil, a new antianginal agent.

Authors:  E Winslow; K A Kane
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jul-Aug       Impact factor: 3.105

6.  Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.

Authors:  K A Kane; E Winslow
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

7.  Electrophysiological effects of lidocaine, l-chlorpheniramine, and bepridil on rabbit sinus node pacemaker cells.

Authors:  K A Kane; G Y Berdeja García; S Sánchez-Pérez; G Pastelín
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

8.  Electrophysiological effects of lidocaine, l-chlorpheniramine, and bepridil on normal and ouabain-intoxicated canine Purkinje fibers.

Authors:  K A Kane; G Y Berdeja García; S Sánchez-Pérez; G Pastelín
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

9.  Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound.

Authors:  D Cosnier; P Duchenne-Marullaz; G Rispat; G Streichenberger
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-01

10.  Cardiac effects of cibenzoline.

Authors:  K H Dangman
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

View more
  3 in total

1.  Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres.

Authors:  F Berger; U Borchard; D Hafner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

2.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

Review 3.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.